In:
Cancer, Wiley, Vol. 128, No. 7 ( 2022-04), p. 1467-1474
Abstract:
Thalidomide could prolong the latency period and reduce the incidence of oral mucositis in patients who have received concurrent chemoradiotherapy for nasopharyngeal carcinoma. Thalidomide administration is well tolerated and safe.
Type of Medium:
Online Resource
ISSN:
0008-543X
,
1097-0142
Language:
English
Publisher:
Wiley
Publication Date:
2022
detail.hit.zdb_id:
1479932-7
detail.hit.zdb_id:
2599218-1
detail.hit.zdb_id:
2594979-2
detail.hit.zdb_id:
1429-1